ArticleMedicine2026
Cause-specific mortality in a population-level cohort of pancreatic cancer patients following chemotherapy: A SEER-based study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Suicide Risk and Associated Factors in Patients with Pancreatic Cancer: A Systematic Review.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic adenocarcinoma remains highly lethal. How modern chemotherapy reshapes the full mortality profile, including competing non‑cancer deaths, is incompletely defined. Using Surveillance, Epidemiology, and End Results (2010-2021), we identified 9624 adults (20-89 years) with primary pancreatic adenocarcinoma who received systemic chemotherapy. Cause of death (International Classification of Diseases, Tenth Revision) was classified as pancreatic cancer, other cancers, or non‑cancer causes. Stage-stratified analyses characterized mortality heterogeneity. Standardized mortality ratios (SMRs) versus the general US population were calculated in SEER*Stat; multivariable Poisson regression assessed risk factors. Temporal patterns were examined across ≤1 year, 1 to 5 years, and >5 years from diagnosis. Over a median follow-up of 14.2 months, 8218 deaths occurred. Pancreatic cancer accounted for 90.6% (n = 7448); non‑cancer causes accounted for 6.1% (n = 498), and other cancers accounted for 3.3% (n = 272). Non-cancer mortality comprised 7.8% of stage I/II deaths versus 5.1% in stage III/IV, reflecting longer survival enabling competing risks. Overall, non‑cancer mortality was markedly elevated (SMR 15.38, 95% confidence interval: 14.06-16.79), peaking in year 1 (SMR 96.10) and declining thereafter (1-5 years, SMR 13.63; >5 years, SMR 3.19). Cardiovascular deaths carried the greatest non‑cancer burden (heart disease SMR 9.96; cerebrovascular disease SMR 12.7). Infectious causes showed the highest relative risks (septicemia SMR 20.3; pneumonia/influenza SMR 88.69), concentrated in the first year. Chronic obstructive pulmonary disease (SMR 17.57) and diabetes (SMR 19.3) were additional contributors. Older patients (70-89 years) experienced the steepest early mortality. Suicide risk was strikingly increased (SMR 113.68), underscoring substantial psychological distress. In chemotherapy‑treated pancreatic cancer, non‑cancer mortality is substantial, time‑dependent, and dominated by cardiovascular and infectious causes in the first year after diagnosis. These data support integrated cardio‑oncology pathways, aggressive infection prevention, metabolic and pulmonary co‑management, and early psychosocial interventions to reduce preventable deaths and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.